Silence Therapeutics plc
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
11. Other intangible assets
Intangible assets as of December 31, 2025 are as follows:
| Year ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| $000s | $000s | |
| License and software | 481 | 481 |
| Accumulated Depreciation | (193) | (169) |
| License and software, net | 288 | 312 |
The intangible assets are amortized beginning from the date of acquisition, over their useful life or written down if they are considered to be impaired.
Amortization expense is included in General and administrative expenses, which included on the consolidated statements of income (loss), and was nominal for the years ended December 31, 2025 and 2024, respectively.
Expected future amortization expense is as follows:
| Year | Expected Amortization |
|---|---|
| $000s | |
| 2026 | 46 |
| 2027 | 41 |
| 2028 | 41 |
| 2029 | 41 |
| 2030 | 41 |
| Thereafter | 78 |
No impairment charges related to intangible assets were recorded for the years ended December 31, 2025 and 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.